They were having discussions with FDA on the possibility of accelerated approval for SRP-9001 (which has shown DMD treatment efficacy in Phase 2 trials) since April. Most analysts didn’t give them much chance (still to complete phase 3). Then on July 29th they went into a trading halt at circa $85 and announced that will formally apply for accelerated approval, which meant that talks with the FDA had been positive.
The stock rose 33% to circa $114 in the 7 days after trading resumed.
I got this off publicly available announcements, not because I work for Sarepta (attn. Monti, RYN etc. lol)
For General Information, page-1105
-
- There are more pages in this discussion • 2,423 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.5¢ | 10.5¢ | $242.1K | 2.246M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 47453 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 278209 | 3 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |